An extended release formulation of molindone shows promise as an adjunctive treatment for refractory impulsive aggression among children administered stimulant monotherapy for ADHD.
Verapamil adjuvant therapy showed no benefit versus placebo in patients with refractory epilepsy on standard antiepileptic drug (AED) treatment
DMF was associated with lower annualized relapse rates (ARR) and improvement on patient reported outcomes (PROs) in patients with relapsing multiple sclerosis (RMS) who switch to DMF following suboptimal response to glatiramer acetate (GA).
Patients with relapsing-remitting multiple sclerosis (MS) had fewer relapses after switching from glatiramer acetate to fingolimod versus remaining on the injectable disease-modifying therapy
In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium.
Delayed-release dimethyl fumarate (DMF) is associated with better control of multiple sclerosis (MS)-associated declines in work productivity than the injectable platform therapies
At 12 months, patients with relapsing-remitting multiple sclerosis (MS) treated with dimethyl fumarate and fingolimod had similar rates of overall efficacy and adherence, but patients discontinued dimethyl fumigate earlier than fingolimod.
In the “real world,” patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were higher than those observed in clinical trials.
Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.
The advantages of fingolimod over injectable disease-modifying therapies (iDMTs) in patient retention and treatment satisfaction support use of fingolimod in early relapsing-remitting multiple sclerosis (MS) in the real world.
